SANDOSTATIN LAR Drug Patent Profile

Which patents cover Sandostatin Lar, and what generic alternatives are available?

Sandostatin Lar is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in SANDOSTATIN LAR is octreotide acetate. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sandostatin Lar

A generic version of SANDOSTATIN LAR was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8^th, 2005.

Summary for SANDOSTATIN LAR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	78
Patent Applications:	680
Drug Prices:	Drug price information for SANDOSTATIN LAR
DailyMed Link:	SANDOSTATIN LAR at DailyMed

See drug prices for SANDOSTATIN LAR

Recent Clinical Trials for SANDOSTATIN LAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Clinica Universidad de Navarra, Universidad de Navarra	Phase 2
University Hospital, Antwerp	Phase 4
ZonMw: The Netherlands Organisation for Health Research and Development	Phase 4

See all SANDOSTATIN LAR clinical trials

US Patents and Regulatory Information for SANDOSTATIN LAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-001	Nov 25, 1998	AB	RX	Yes	No
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-002	Nov 25, 1998	AB	RX	Yes	No
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-003	Nov 25, 1998	AB	RX	Yes	Yes

Expired US Patents for SANDOSTATIN LAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-002	Nov 25, 1998	5,538,739*PED
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-003	Nov 25, 1998	5,538,739*PED
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-003	Nov 25, 1998	5,922,682*PED
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-002	Nov 25, 1998	5,922,338*PED

International Patents for SANDOSTATIN LAR

See the table below for patents covering SANDOSTATIN LAR around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	16492	PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN ANALOGUES
China	1520895
Hungary	912452
Netherlands	9001537

Supplementary Protection Certificates for SANDOSTATIN LAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0029579	SPC/GB93/097	United Kingdom

SANDOSTATIN LAR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Sandostatin LAR

Introduction to Sandostatin LAR

Sandostatin LAR, a long-acting formulation of the somatostatin analog lanreotide, is a crucial therapeutic option for managing conditions caused by excessive growth hormone secretion, such as acromegaly and neuroendocrine tumors. This drug is administered via deep subcutaneous injection, providing a sustained release of medication over time[4].

Global Market Size and Growth

The global Sandostatin LAR market is projected to experience significant growth from 2024 to 2031. The market size is estimated to be USD XX million in 2024 and is expected to expand at a Compound Annual Growth Rate (CAGR) of 5.0% during the forecast period, reaching USD XX million by 2031[1].

Regional Market Dynamics

North America

North America currently dominates the Sandostatin LAR market, driven by increasing diagnoses of neuroendocrine tumors and acromegaly. Enhanced awareness, improved healthcare access, and supportive reimbursement regulations contribute to the growing demand in this region. The CAGR for North America is expected to be around 3.2% from 2024 to 2031, with the United States and Canada showing CAGRs of 3% and 4%, respectively[1].

Europe

Europe is another significant market for Sandostatin LAR, with a CAGR of 5% from 2024 to 2031. The UK, in particular, is expected to grow at a CAGR of 4.3% during the same period[1].

Asia-Pacific

The Asia-Pacific region is anticipated to make substantial gains, with the highest CAGR of 7.0% from 2024 to 2031. This growth is attributed to the rising prevalence of neuroendocrine tumors and acromegaly, along with improved healthcare infrastructure and greater access to treatments[1].

Latin America and Middle East & Africa

Latin America and the Middle East & Africa also show promising growth, with CAGRs of 4.4% and 4.7%, respectively, from 2024 to 2031. These regions are benefiting from increasing healthcare spending and improvements in healthcare infrastructure[1].

Product Segments

Dosage Forms

The Sandostatin LAR market is segmented based on dosage forms, with the 500mcg formulation currently dominating the market due to its effectiveness and convenient dosing schedule. However, the 1000mcg formulation is the fastest-growing segment, offering effective control for advanced neuroendocrine tumors and acromegaly[1].

Applications

Acromegaly and Neuroendocrine Tumors

Sandostatin LAR is primarily used to treat acromegaly and neuroendocrine tumors. Its ability to inhibit hormone secretion helps control symptoms and improve patients' quality of life. The increasing prevalence of these conditions is a key driver of market growth[4].

Other Applications

In addition to its primary uses, Sandostatin LAR is also used for other conditions such as bleeding esophageal varices. However, these applications are less prominent compared to its use in treating hormonal disorders[3].

Financial Trajectory

Revenue Growth

The financial trajectory of the Sandostatin LAR market is marked by steady revenue growth. The market's expansion is driven by increasing demand for effective treatments for hormonal disorders, particularly in regions with improving healthcare infrastructure and favorable regulatory environments[1][4].

Investment Opportunities

Investing in the Sandostatin LAR market presents substantial opportunities due to the growing aging population and the increasing prevalence of hormonal disorders. Companies involved in the development and distribution of Sandostatin LAR and similar therapies are likely to benefit from these trends[4].

Regulatory Environment

Favorable Regulations

The favorable regulatory environment in many regions enhances investment opportunities. Streamlined approval processes for medications like Sandostatin LAR facilitate market entry, especially in emerging markets where healthcare infrastructure is improving[4].

Compliance Challenges

Despite the favorable environment, the Sandostatin LAR market faces challenges related to regulatory compliance. Manufacturers must invest in compliance strategies to navigate the complex landscape of drug approvals and ensure adherence to varying regulations across different countries[4].

Competitive Landscape

Increasing Competition

The Sandostatin LAR market is characterized by increasing competition from other therapeutic options. Established brands must continually innovate and enhance their product offerings to maintain a competitive edge. Price pressure and the need for differentiation are critical in this dynamic landscape[4].

Recent Trends and Innovations

Innovations in Drug Delivery

Recent trends include innovations in drug delivery systems, which are improving patient adherence and treatment outcomes. Expanded clinical trials for new indications and partnerships for research and development are also driving market growth[4].

Clinical Trials and Research

Ongoing research initiatives and collaborations with healthcare companies are supporting the growth of the Sandostatin LAR market. These efforts are focused on expanding the therapeutic uses of the drug and improving its efficacy[4].

Key Takeaways

• The global Sandostatin LAR market is expected to grow at a CAGR of 5.0% from 2024 to 2031.
• North America dominates the market, but the Asia-Pacific region is expected to show the highest growth rate.
• The 500mcg and 1000mcg formulations are key drivers of market growth.
• Increasing prevalence of hormonal disorders and a favorable regulatory environment are significant market drivers.
• Regulatory compliance and competition are key challenges facing the market.
• Innovations in drug delivery and ongoing research initiatives are enhancing market growth.

FAQs

What is Sandostatin LAR used for?

Sandostatin LAR is primarily used to treat conditions caused by excessive growth hormone secretion, such as acromegaly and neuroendocrine tumors.

What is the expected CAGR of the Sandostatin LAR market from 2024 to 2031?

The global Sandostatin LAR market is expected to grow at a CAGR of 5.0% from 2024 to 2031.

Which region is expected to show the highest growth rate for Sandostatin LAR?

The Asia-Pacific region is anticipated to show the highest CAGR of 7.0% from 2024 to 2031.

What are the main challenges facing the Sandostatin LAR market?

The main challenges include regulatory compliance and increasing competition from other therapeutic options.

How does the regulatory environment impact the Sandostatin LAR market?

The favorable regulatory environment in many regions enhances investment opportunities by streamlining approval processes, especially in emerging markets.

What are the recent trends in the Sandostatin LAR market?

Recent trends include innovations in drug delivery systems, expanded clinical trials for new indications, and partnerships for research and development.

Sources

1. Cognitive Market Research: Sandostatin LAR Market Report 2024 (Global Edition)
2. Novartis: Novartis Financial Results Q4 2022 – English
3. Market Research Intellect: Sandostatin Lar Drugs Market Size And Forecast
4. Market Research Intellect: Sandostatin Lar Market Size And Projection
5. Novartis: Novartis delivers 12% sales and 21% core operating income growth ...